Skye Bioscience director sells 33,892 shares
Skye Bioscience, Inc. (SKYE) director and ten percent owner Andrew J. Schwab, through affiliated 5AM funds, reported open-market sales of Skye common stock on September 16, 2026.
Rhea-AI Filing Summary
Skye Bioscience, Inc. (SKYE) director and ten percent owner Andrew J. Schwab, through affiliated 5AM funds, reported open-market sales of Skye common stock on September 16, 2026. 5AM Ventures II, L.P. sold 32,607 shares and 5AM Co-Investors II, L.P. sold 1,285 shares at a weighted average of $1.91 per share, with execution prices ranging from $1.70 to $2.11. After these transactions, the entities associated with Schwab report indirect holdings of 142,463 shares (5AM Ventures II), 5,616 shares (5AM Co-Investors II) and 981,269 shares (5AM Ventures VII), with Schwab disclaiming beneficial ownership beyond his pecuniary interest. No Rule 10b5-1 trading plan is reported. A prior 1-for-8 reverse stock split effective August 24, 2026 is reflected in these share amounts.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 33,892 shares
Net Sell
3 txns
Insider
Schwab Andrew J.
Role
Director, 10% Owner
Sold
33,892 shs ($65K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 32,607 | $1.91 | $62K |
| Sale | Common Stock F1, F3 | 1,285 | $1.91 | $2K |
| holding | Common Stock F4 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 142,463 shares (Indirect, By 5AM Ventures II, L.P.);
Common Stock — 5,616 shares (Indirect, By 5AM Co-Investors II, L.P.);
Common Stock — 981,269 shares (Indirect, By 5AM Ventures VII, L.P.)
Footnotes (4)
- F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70 to $2.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2. The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- F3. The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. The Reporting Person is a managing member of Partners II and may be deemed to have shared voting and investment power over the shares beneficially owned by Co-Investors II. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- F4. The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Key Figures
Shares sold by 5AM Ventures II, L.P.: 32,607 shares
Shares sold by 5AM Co-Investors II, L.P.: 1,285 shares
Total shares sold: 33,892 shares
+5 more
8 metrics
Shares sold by 5AM Ventures II, L.P.
32,607 shares
Open-market sale of Skye common stock on September 16, 2026
Shares sold by 5AM Co-Investors II, L.P.
1,285 shares
Open-market sale of Skye common stock on September 16, 2026
Total shares sold
33,892 shares
Combined sales by 5AM Ventures II, L.P. and 5AM Co-Investors II, L.P. on September 16, 2026
Weighted average sale price
$1.91 per share
Sales executed in a price range from $1.70 to $2.11
Price range of sales
$1.70–$2.11 per share
Execution prices for the September 16, 2026 transactions
Post-transaction holdings via 5AM Ventures II, L.P.
142,463 shares
Indirectly beneficially owned after September 16, 2026 sale
Post-transaction holdings via 5AM Co-Investors II, L.P.
5,616 shares
Indirectly beneficially owned after September 16, 2026 sale
Indirect holdings via 5AM Ventures VII, L.P.
981,269 shares
Reported as indirectly held with no transaction on that date
Key Terms
weighted average price, reverse stock split, beneficial ownership, pecuniary interest
4 terms
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
reverse stock split financial
"the Issuer effected a 1-for-8 reverse stock split of its Common Stock"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
beneficial ownership financial
"shares beneficially owned by Ventures II"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"disclaims beneficial ownership of such securities except to the extent of his pecuniary interest"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Skye Bioscience (SKYE) report for Andrew J. Schwab?
Andrew J. Schwab reported indirect sales of Skye Bioscience common stock on September 16, 2026 by 5AM Ventures II, L.P. and 5AM Co-Investors II, L.P., plus updated indirect holdings through 5AM Ventures VII, L.P.
What prices were received in the Skye (SKYE) insider sales on September 16, 2026?
The reported price is a weighted average of $1.91 per share, with the shares sold in multiple transactions at prices ranging from $1.70 to $2.11 inclusive.
What are Andrew J. Schwab’s indirect Skye (SKYE) holdings after these transactions?
After the reported sales, indirect holdings are 142,463 shares by 5AM Ventures II, L.P., 5,616 shares by 5AM Co-Investors II, L.P., and 981,269 shares by 5AM Ventures VII, L.P., with Schwab disclaiming beneficial ownership beyond his pecuniary interest.
Were the Skye (SKYE) insider sales made under a Rule 10b5-1 trading plan?
No. The filing indicates no Rule 10b5-1 trading plan; the document-level checkbox for trades under such a plan is not marked, and no footnote describes a trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
